DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Losartan Therapy in Pulmonary Hypertension

Information source: Baskent University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulmonary Hypertension

Intervention: nifedipine, losartan (Drug); losartan (Drug); Nifedipine, losartan (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Baskent University

Official(s) and/or principal investigator(s):
Serife Savas Bozbas, MD, Principal Investigator, Affiliation: Baskent University Faculty of Medicine, Department of Pulmonary Disease
Fusun Oner Eyuboglu, MD, Study Chair, Affiliation: Baskent University Faculty of Medicine, Department of Pulmonary Disease


In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. These beneficial effects, render those agents appropriate for use in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise test, and endothelin-1 levels. Losartan is as effective as nifedipine for reducing Doppler echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with PHT.

Clinical Details

Official title: Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Pulmonary hypertension diagnosed by Doppler echocardiographic examination (a mean

pulmonary artery pressure of > 26mmHg) Exclusion Criteria:

- acute infectious or inflammatory disease,

- exacerbation of chronic obstructive pulmonary disease,

- malignancy,

- acute coronary syndrome in the last 4 weeks,

- uncontrolled arrhythmia and hypertension,

- decompensated heart failure,

- acute pulmonary emboli,

- thrombus in a lower extremity,

- oxygen saturation below 85% at rest,

- failure to cooperate with CPET

Locations and Contacts

Additional Information

Starting date: January 2005
Last updated: August 22, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017